Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1991-09-06
1993-11-16
Rollins, John W.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
A61K 3578
Patent
active
052621626
ABSTRACT:
The use of an effective monoamine oxidase-inhibitory amount or portion of black currant juice (Ribes nigrum L.) or concentrate or dry extract thereof to activate the brain and central nervous system, in a living animal, especially a human being, in need thereof, and thereby to increase the general cerebral performance, especially in healthy and elderly people, and for the prevention, treatment, and alleviation of neurodegenerative diseases associated with reduced cerebral performance, such as Parkinson's disease, dementia, and mood disorders, and compositions thereof for such purpose, are disclosed.
REFERENCES:
patent: 4703060 (1987-10-01), Traitler et al.
Chem. Abst., 109:72306w, 1988.
Chem. Abst., 110:3397t, 1989.
Chem. Abst., 111:95699g, 1989.
Chem. Abst., 112:34640e, 1990.
Drugs & Pharmacology 1989-1990 #20, 1 of 1, "Selegiline versus oxiracetam in patients with Alzheimer-type dementia", Falsaperla, et al. (Abstracting Clinther. 12/5, 376-384 (1990).
Drugs & Pharmacology 1991-Apr. 1992 #28, 1 of 8, "L-deprenyl therapy improves verbal memory in amnesic alzheimer patients", Finali, et al. (Abstracting Clinneuropharmacol 14/6 523-536 (1991).
Drugs & Pharmacology 1991-4/92 #28, 2 of 8, "The use of selegiline in Alzeimer's patients with behavior problems", Goad, et al. (Abstracting J-Clinpsychiatry, 52/8 342-345 (1991).
Drugs & Pharmacology 1991-Apr. 1992 #28, 3 of 8, "A pilot study of low-dose L-deprenyl in Alzheimer's disease", Schneider, et al. (Abstracting J-Geriatrpsychiatry-Neurol, 4/3, 143-148 (1991).
Drugs & Pharmacology 1989-1990 #28, 6 of 8, "Selegiline in the treatment of mild to moderate Alzheimer-type dementia", Monteverde, et al. (Abstracting Clin-Ther. 12/4, 315-322 (1990)).
Drugs & Pharmacology 1987-1988 #28, 8 of 8, "Cognitive effects of L-deprenyl in Alzheimer's disease", Tariot, et al. (Abstracting Psychopharmacology, 91/4, 489-495 (1987).
11 Mezz, 87212378, "L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition", Tariot, et al. (Abstracting Arch-Gen-Psychiatry, 44(5), 427-433 (May 1987).
Psychopharmacologia (Berl.) 13, 222-257 (1988); Irwin, "Compressive Observational Assessment etc.".
Neuropsychobiology 18: 212-218 (1987), "Radioelectroencephalographic comparison of memantine with receptor-specific drugs acting on dopaminergic transmission in freely moving rats", Dimfel, et al.
Neurophychobiology 19: 116-120 (1988), "Monitoring of the effects of antidepressant drugs in the freely moving rat by radioelectroencephalography (tele-stero-EEG)", Dimpfel, et al.
13 Mezz, 81099269, "Deprenyl in Parkinson Disease", Eisler, et al. (Abstracting Neurology 31(1), 19-23 (Jan. 1981).
1 Mezz, "Deprenyl effects on levodopa pharmacodynamics, mood, and free radiaca scavenging", Baronti, et al. (Abstrcting Neurology 42 (3 Pt 1), 541-544 (Mar. 1992)).
Drugs & Pharmacology 1980-1981, #30 , 2 of 2, "Antidepressant potentiation of 5-hydroxytryptophan by L-Deprenil in affective illness" (Abstracting J-Affect-Disord. 2/2, 137-146 (1980)).
Acta Neurologica Scandinavica, No. 136, vol. 84, 1991, "New approaches to the treatment of early Parkinson's disease", U. K. Rinne, et al., pp. 70, 73, 79, 87.
Meth and Find Exptl Clin Pharmacol 1987; 9(6): 385-408, "Topographic brain mapping of EEG in neuropsychopharmacology--Part II. Clinical applications" (Pharmaco EEG Imaging), Saletu, et al.
Z.EEG-EMG 12 (1981) 21-32, "Beispiele fur die Projektiovon Substanzwirkungen typischer Psychopharmaka auf eine elektriphysiologische MeBebene", Hermann, et al.
Human Psychopharmacology Measures and Methods, vol. 1, Edited by I. Hindmarch and P. D. Stonier, A Wiley Medical Publication, 1986, pp. 176-179 and 184 (B. Saletu, "The Use of Pharmaco-EEG in Drug Profiling").
J. Ment. Sci. (1960), "Drugs and Personality", VIII. The effects of stimulant and depressant drugs on visual after-effects of a rotating spiral, Eysenck, et al., pp. 842-844.
Perception & Psychophysics, 1987, 41 (1), 17-22, "Interaction of signal discriminability and task type in vigilance decrement," Parsuraman, et al., Copyright 1987 Psychonomic Society, Inc.
Elsevier, 1988, "Comparative Evaulation of Rating Scales for Clinical Psychopharmacology", van Riezen, et al., pp. 78-79.
Martindale, "The extra pharmacopoeia", London, The Pharmaceutical Press 1255 and 1257 (1989).
Martindale, "The extra pharmacopoeia", London, The Pharmaceutical Press 1255 and 1257 (1989).
EPO Search Report EP 92308063 dated Dec. 15, 1992.
Armstrong, "Recent Trends in Research and Treatment of Parkinson's Disease", SCRIP pp. 58-61 and 63-67 (May 1989).
Bormann Joachim
Demisch Lothar
Gurtelmeyer Roman
Koch Rudinger
Schatton Wolfgang
Hueschen Gordon W.
Merz & Co. GmbH & Co.
Rollins John W.
LandOfFree
Cerebral-activating extract does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cerebral-activating extract, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cerebral-activating extract will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-20771